Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation ; volume:26 ; number:5 ; day:24 ; month:7 ; year:2024 ; pages:1-14 ; date:10.2024
The AAPS journal / American Association of Pharmaceutical Scientists ; 26, Heft 5 (24.7.2024), 1-14, 10.2024
- Creator
-
Karsten, Carley
Grannas, Karin
Bergman, Oskar
Movérare, Robert
Roforth, Matthew
Willrich, Maria Alice V.
Snyder, Melissa R.
Yang, Yifei K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1208/s12248-024-00953-3
- URN
-
urn:nbn:de:101:1-2412172109386.914013270938
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Karsten, Carley
- Grannas, Karin
- Bergman, Oskar
- Movérare, Robert
- Roforth, Matthew
- Willrich, Maria Alice V.
- Snyder, Melissa R.
- Yang, Yifei K.
- SpringerLink (Online service)
Other Objects (12)
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties
Sensitivity of assays for TSH-receptor antibodies
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Aktivitäts- und Verlaufsparameter unter neu initiierter Therapie mit Antagonisten gegen Tumornekrosefaktor alpha : Infliximab, Etanercept und Adalimumab im Vergleich
Aktivitäts- und Verlaufsparameter unter neu initiierter Therapie mit Antagonisten gegen Tumornekrosefaktor alpha : Infliximab, Etanercept und Adalimumab im Vergleich
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties
Sensitivity of assays for TSH-receptor antibodies
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Aktivitäts- und Verlaufsparameter unter neu initiierter Therapie mit Antagonisten gegen Tumornekrosefaktor alpha : Infliximab, Etanercept und Adalimumab im Vergleich
Aktivitäts- und Verlaufsparameter unter neu initiierter Therapie mit Antagonisten gegen Tumornekrosefaktor alpha : Infliximab, Etanercept und Adalimumab im Vergleich
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties
Sensitivity of assays for TSH-receptor antibodies
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Aktivitäts- und Verlaufsparameter unter neu initiierter Therapie mit Antagonisten gegen Tumornekrosefaktor alpha : Infliximab, Etanercept und Adalimumab im Vergleich